Back to Search
Start Over
Identification macrophage signatures in prostate cancer by single-cell sequencing and machine learning.
- Source :
-
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Feb 13; Vol. 73 (3), pp. 41. Date of Electronic Publication: 2024 Feb 13. - Publication Year :
- 2024
-
Abstract
- Background: The tumor microenvironment (TME) encompasses a variety of cells that influence immune responses and tumor growth, with tumor-associated macrophages (TAM) being a crucial component of the TME. TAM can guide prostate cancer in different directions in response to various external stimuli.<br />Methods: First, we downloaded prostate cancer single-cell sequencing data and second-generation sequencing data from multiple public databases. From these data, we identified characteristic genes associated with TAM clusters. We then employed machine learning techniques to select the most accurate TAM gene set and developed a TAM-related risk label for prostate cancer. We analyzed the tumor-relatedness of the TAM-related risk label and different risk groups within the population. Finally, we validated the accuracy of the prognostic label using single-cell sequencing data, qPCR, and WB assays, among other methods.<br />Results: In this study, the TAM&#95;2 cell cluster has been identified as promoting the progression of prostate cancer, possibly representing M2 macrophages. The 9 TAM feature genes selected through ten machine learning methods and demonstrated their effectiveness in predicting the progression of prostate cancer patients. Additionally, we have linked these TAM feature genes to clinical pathological characteristics, allowing us to construct a nomogram. This nomogram provides clinical practitioners with a quantitative tool for assessing the prognosis of prostate cancer patients.<br />Conclusion: This study has analyzed the potential relationship between TAM and PCa and established a TAM-related prognostic model. It holds promise as a valuable tool for the management and treatment of PCa patients.<br /> (© 2024. The Author(s).)
Details
- Language :
- English
- ISSN :
- 1432-0851
- Volume :
- 73
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Cancer immunology, immunotherapy : CII
- Publication Type :
- Academic Journal
- Accession number :
- 38349474
- Full Text :
- https://doi.org/10.1007/s00262-024-03633-5